This technology is an automated, high-throughput epigenomic mapping method that leverages chromatin immunoprecipitation-sequencing (ChIP-seq) to comprehensively profile chromatin states of low-cell input samples.
Current epigenomic mapping techniques, like chromatin immunoprecipitation-sequencing (ChIP-seq), provide valuable insights into chromatin states but are often limited by cell viability, resolution, scalability, and the ability to capture complex chromatin interactions across diverse cell types. Further, these techniques are limited due to the need to obtain large sample quantities, thereby making it difficult to find applications in clinical diagnostics. As a result, significant gaps remain in mapping epigenetic changes in disease contexts, limiting the discovery of biomarkers and therapeutic targets. Addressing these limitations is crucial for advancing personalized medicine and better understanding the epigenetic underpinnings of diseases.
This technology is an automated, high-throughput, and low-cell input protocol for performing chromatin immunoprecipitation-sequencing (ChIP-seq). This approach utilizes a liquid handler automation script for performing ultrasound sonication for fragmentation of chromatin into uniform 300-500bp fragments for both next-generation sequencing (NGS) applications and antibody-binding for chromatin-bound protein assays. As a result, this platform can multiplex ChIP-seq at 5,000+ cells, enabling potential applications in clinical diagnostics. This system can potentially be used as a discovery-based research tool for epigenetics-based core facilities and a system for clinical diagnostics.
Patent Pending (US20250043329)
IR CU23333
Licensing Contact: Joan Martínez